Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives

The term metabolic-associated fatty liver disease (MAFLD), with a global prevalence estimated at 38.77%, has gradually replaced the traditional concept of non-alcoholic fatty liver disease (NAFLD). Compared to the general population, the incidence of MAFLD is notably higher among pregnant women, posing potential risks to both maternal and neonatal health. This review summarizes the latest research on MAFLD, focusing on its association with pregnancy complications. Additionally, it provides a comparative analysis with previous studies on NAFLD, presenting a comprehensive perspective for clinical management. Findings suggest that pregnant women with MAFLD face a higher risk of gestational hypertension and cesarean delivery compared to those with NAFLD, while the risk for gestational diabetes mellitus remains similar between the two conditions. Additionally, MAFLD is associated with an increased likelihood of delivering large-for-gestational-age infants and heightened risks of preterm birth and low birth weight. Current treatment strategies for MAFLD focus on lifestyle modifications, such as dietary adjustments and increased physical activity. However, there is an urgent need for the development of safe and effective pharmacological treatments, particularly tailored toward pregnant women. Future research should delve deeper into the causal relationships between MAFLD and pregnancy complications and explore optimal therapeutic approaches to improve outcomes for mothers and their infants. Metabolic-associated fatty liver disease and pregnancy complicationsMetabolic-associated fatty liver disease (MAFLD) is a new term for what used to be called non-alcoholic fatty liver disease, affecting nearly two-fifths of people worldwide. It's especially concerning for pregnant women, as it can cause serious problems for both the mother and the baby. This summary looks at the latest studies on how MAFLD affects pregnant women and how it compares to the older diagnosis of NAFLD. The findings show that pregnant women with MAFLD are more likely to have high blood pressure during pregnancy and need a cesarean section. However, the chance of getting gestational diabetes is about the same for both MAFLD and NAFLD. MAFLD also increases the risk of having a baby that is too large for its gestational age, as well as the risks of preterm birth and low birth weight. Right now, the main way to treat MAFLD is through healthy lifestyle changes like diet and exercise. But there's a big need for new medicines that are safe for pregnant women. Future studies should look more into how MAFLD causes complications during pregnancy and find the best ways to treat it to help mothers and their babies.